Large-scale studies to identify biomarkers for heart disease: A role for proteomics?

Expert Opinion on Medical Diagnostics

Volumn 3, Issue 2, 2009, Pages 133-141

  Chugh, Shaan ^a,b   Liu, Peter ^c   Emili, Andrew ^b,d,e   Gramolini, Anthony ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HEART AND STROKE FOUNDATION OF CANADA   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d Banting and Best Department of Medical Research   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomarkers; Cardiac disease; Cardiovascular medicine; Proteomics

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYSTATIN C; HOMOCYSTEINE; HORMONE PRECURSOR; INTERLEUKIN 6; MICRORNA; MYOSIN LIGHT CHAIN 2; SERUM AMYLOID A; TROPONIN I;

CLINICAL MEDICINE; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ELECTROSPRAY; GENE EXPRESSION PROFILING; HEART DISEASE; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE INJURY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; MESENCHYMAL STEM CELL; MOLECULAR BIOLOGY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVIEW; STEM CELL TRANSPLANTATION; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 77953380709     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530050902721215     Document Type: Review

References (68)

1. Kislinger T, Emili A. Going global: protein expression profiling using shotgun mass spectrometry. Curr opin Mol Ther 2003;5(3):285-293 (Pubitemid 37185348)
2. Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature 2003;422(6928):198-207 (Pubitemid 36362757)
3. Collinson PO, Gaze DC. Biomarkers of cardiovascular damage and dysfunction-an overview. Heart Lung Circn 2007;16(Suppl 3):S71-82 (Pubitemid 47233297)
4. Edwards AV, White MY, Cordwell SJ. The role of proteomics in clinical cardiovascular biomarker discovery. Mol Cell Proteomics 2008;7(10):1824-1837
5. Shake JG, Gruber PJ, Baumgartner WA, et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann Thorac Surg 2002;73(6):1919-25; discussion 26 (Pubitemid 34596742)
6. Fu Q, Van Eyk JE. Proteomics and heart disease: identifying biomarkers of clinical utility. Expert Rev Proteomics 2006;3(2):237-249 (Pubitemid 43987850)
7. Govender P, Baugh JA, Pennington SR, et al. Role of proteomics in the investigation of pulmonary fibrosis. Expert Rev Proteomics 2007;4(3):379-388 (Pubitemid 46890075)
8. Omenn GS, States DJ, Adamski M, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005;5(13):3226-3245 (Pubitemid 41192032)
9. Suzuki T, Nagai R. Molecular markers for cardiovascular disease: cardiovascular biomarkers to proteomic discovery. Nat Clin Pract 2008;5(6):295 (Pubitemid 351761697)
10. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49(16):1733-1739 (Pubitemid 46589928)
11. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 2008;451(7181):949-952 (Pubitemid 351301751)
12. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106(23):2961-2966 (Pubitemid 35424749)
13. Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003;107(5):721-726 (Pubitemid 36222600)
14. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Eng J Med 2008;358(20):2107-2116 (Pubitemid 351679597)
15. Lee KW, Hill JS, Walley KR, Frohlich JJ. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort. CMAJ 2006;174(4):461-466 (Pubitemid 43294860)
16. McGregor E, Dunn MJ. Proteomics of the heart: unraveling disease. Circ Res 2006;98(3):309-321 (Pubitemid 43755327)
17. Agnetti G, Bezstarosti K, Dekkers DH, et al. Proteomic profiling of endothelin-1-stimulated hypertrophic cardiomyocytes reveals the increase of four different desmin species and alpha-B-crystallin. Biochim Biophys Acta 2008;1784(7-8):1068-1076
18. Buscemi N, Murray C, Donerty-Kirby A, et al. Myocardial subproteomic analysis of a constitutively active Rac1-expressing transgenic mouse with lethal myocardial hypertrophy. Am J Physiol 2005;289(6):H2325-33 (Pubitemid 41698539)
19. Gygi SP, Rist B, Griffin TJ, et al. Proteome analysis of low-abundance proteins using multidimensional chromatography and isotope-coded affinity tags. J Proteome Res 2002;1(1):47-54
20. Morano I, Wankerl M, Bohm M, et al. Myosin P-light chain isoenzymes in the human heart: evidence for diphosphorylation of the atrial P-LC form. Basic Res Cardiol 1989;84(3):298-305 (Pubitemid 19166438)
21. Bell JR, Kennington E, Fuller W, et al. Characterization of the phospholemman knockout mouse heart: depressed left ventricular function with increased Na-K-ATPase activity. Am J Physiol 2008;294(2):H613-21 (Pubitemid 351253272)
22. Fuller W, Eaton P, Bell JR, Shattock MJ. Ischemia-induced phosphorylation of phospholemman directly activates rat cardiac Na/K-ATPase. FASEB J 2004;18(1):197-199
23. Chu G, Kerr JP, Mitton B, et al. Proteomic analysis of hyperdynamic mouse hearts with enhanced sarcoplasmic reticulum calcium cycling. FASEB J 2004;18(14):1725-1727 (Pubitemid 39561664)
24. Pan Y, Kislinger T, Gramolini AO, et al. Identification of biochemical adaptations in hyper- or hypocontractile hearts from phospholamban mutant mice by expression proteomics. Proc Nat Acad Sci USA 2004;101(8):2241-2246 (Pubitemid 38269296)
25. Kuster B, Schirle M, Mallick P, Aebersold R. Scoring proteomes with proteotypic peptide probes. Nat Rev 2005;6(7):577-583 (Pubitemid 40943048)
26. Solaro RJ. Remote control of A-band cardiac thin filaments by the I-Z-I protein network of cardiac sarcomeres. Trends Cardiovasc Med 2005;15(4):148-152 (Pubitemid 41138879)
27. Kislinger T, Rahman K, Radulovic D, et al. PRISM, a generic large scale proteomic investigation strategy for mammals. Mol Cell Proteomics 2003;2(2):96-106
28. Sandhu C, Connor M, Kislinger T, et al. Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. J proteome Res 2005;4(3):674-689 (Pubitemid 40863256)
29. Gramolini AO, Kislinger T, Alikhani-Koopaei R, et al. Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Mol Cell Proteomics 2008;7(3):519-533
30. Kane LA, Neverova I, Van Eyk JE. Subfractionation of heart tissue: the 'in sequence' myofilament protein extraction of myocardial tissue. Methods Mol Bio 2007;357:87-90
31. Horvatovich P, Govorukhina N, Bischoff R. Biomarker discovery by proteomics: challenges not only for the analytical chemist. Analyst 2006;131(11):1193-1196 (Pubitemid 44655359)
32. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008;452(7187):571-579
33. Seam N, Gonzales DA, Kern SJ, et al. Quality control of serum albumin depletion for proteomic analysis. Clin Chem 2007;53(11):1915-1920 (Pubitemid 350036035)
34. Baussant T, Bougueleret L, Johnson A, et al. Effective depletion of albumin using a new peptide-based affinity medium. Proteomics 2005;5(4):973-977 (Pubitemid 40469027)
35. Granger J, Siddiqui J, Copeland S, Remick D. Albumin depletion of human plasma also removes low abundance proteins including the cytokines. Proteomics 2005;5(18):4713-4718 (Pubitemid 43016893)
36. Nanni L, Romualdi C, Maseri A, Lanfranchi G. Differential gene expression profiling in genetic and multifactorial cardiovascular diseases. J Mol Cell Cardiol 2006;41(6):934-948 (Pubitemid 44791333)
37. Zong Y, Zhang S, Chen HT, et al. Forward-phase and reverse-phase protein microarray. Methods Mol Biol 2007;381:363-374 (Pubitemid 350189899)
38. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006;5(10):2512-2521 (Pubitemid 44650915)
39. Charboneau L, Tory H, Chen T, et al. Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief funct genomic proteomic 2002;1(3):305-315
40. Paweletz CP, Charboneau L, Bichsel VE, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001;20(16):1981-1989 (Pubitemid 32458030)
41. Janzi M, Odling J, Pan-Hammarstrom Q, et al. Serum microarrays for large scale screening of protein levels. Mol Cell Proteomics 2005;4(12):1942-1947 (Pubitemid 41830188)
42. Talapatra A, Rouse R, Hardiman G. Protein microarrays: challenges and promises. Pharmacogenomics 2002;3(4):527-536 (Pubitemid 34814680)
43. Liotta LA, Espina V, Mehta AI, et al. Protein microarrays: meeting analytical challenges for clinical applications. Cancer cell 2003;3(4):317-325 (Pubitemid 38340301)
44. Arab S, Gramolini AO, Ping P, et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 2006;48(9):1733-1741 (Pubitemid 44648616)
45. Hao Y, Yu Y, Wang L, et al. IPO-38 is identified as a novel serum biomarker of gastric cancer based on clinical proteomics technology. J proteome Res 2008;7(9):3668-3677
46. Ozer J, Ratner M, Shaw M, et al. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245(3):194-205
47. Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5(4):573-588
48. Domon B, Aebersold R. Mass spectrometry and protein analysis. Science 2006;312(5771):212-217
49. Fortin T, Salvador A, Charrier JP, et al. Clinical quantitation of prostate specific antigen biomarker in the low nanogram/mL range by conventional bore liquid chromatography-tandem mass spectrometry (MRM) coupling and correlation with ELISA tests. Mol Cell Proteomics 2008 M800238-MCP200v1
50. Yocum AK, Gratsch TE, Leff N, et al. Coupled global and targeted proteomics of human embryonic stem cells during induced differentiation. Mol Cell Proteomics 2008;7(4):750-767 (Pubitemid 351597485)
51. Heidecker B, Hare JM. The use of transcriptomic biomarkers for personalized medicine. Heart Fail Rev 2007;12(1):1-11 (Pubitemid 46629242)
52. Hwang JJ, Allen PD, Tseng GC, et al. Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics 2002;10(1):31-44 (Pubitemid 135707427)
53. Grzeskowiak R, Witt H, Drungowski M, et al. Expression profiling of human idiopathic dilated cardiomyopathy. Cardiov Res 2003;59(2):400-411 (Pubitemid 37272034)
54. Yung CK, Halperin VL, Tomaselli GF, Winslow RL. Gene expression profiles in end-stage human idiopathic dilated cardiomyopathy: altered expression of apoptotic and cytoskeletal genes. Genomics 2004;83(2):281-297 (Pubitemid 38050117)
55. Minagawa H, Honda M, Miyazaki K, et al. Comparative proteomic and transcriptomic profiling of the human hepatocellular carcinoma. Biochem Biophys Res Commun 2008;366(1):186-192 (Pubitemid 350297227)
56. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Nat Acad Sci USA 2003;100(24):14229-14234 (Pubitemid 37499219)
57. Tan PK, Downey TJ, Spitznagel EL Jr, et al. Evaluation of gene expression measurements from commercial microarray platforms. Nucleic Acids Res 2003;31(19):5676-5684 (Pubitemid 37441938)
58. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat biotechnol 2006;24(9):1151-1161 (Pubitemid 44359727)
59. van Rooji E, Olson EN. microRNAs put their signatures on the heart. Physiol Genomics 2007;31(3):365-366 (Pubitemid 350127776)
60. Yang B, Lu Y, Wang Z. Control of cardiac excitability by microRNAs. Cardiov Res 2008;79(4):571-580
61. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438(7068):685-689
62. Krutzfeldt J, Kuwajima S, Braich R, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res 2007;35(9):2885-2892 (Pubitemid 47073627)
63. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13(5):613-618 (Pubitemid 46828487)
64. Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007;13(4):486-491 (Pubitemid 46559834)
65. Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease. Physiol Genomics 2007;31(3):367-373 (Pubitemid 350127777)
66. Tomita S, Li RK, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999;100(19 Suppl):II247-56 (Pubitemid 29523543)
67. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002;106(24):3009-3017 (Pubitemid 35440281)
68. Van Hoof D, Passier R, Ward-Van Oostwaard D, et al. A quest for human and mouse embryonic stem cell-specific proteins. Mol Cell Proteomics 2006;5(7):1261-1273 (Pubitemid 44103397)